financetom
Business
financetom
/
Business
/
Why Industrial Conglomerate Fortive's Shares Are Sliding Today
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Industrial Conglomerate Fortive's Shares Are Sliding Today
Apr 24, 2024 9:51 AM

Fortive Corporation ( FTV ) shares are trading lower after the company reported first-quarter FY24 results.

Revenue grew 4% Y/Y to $1.525 billion, marginally missing the consensus of $1.527 billion.

Sales by segments: Intelligent Operating Solutions $666 million (+5% Y/Y), Precision Technologies $559 million (+3% Y/Y), and Advanced Healthcare Solutions $300 million (+4% Y/Y).

The company’s adjusted operating margin is up 110 basis points Y/Y to 25.1%, driven by substantial gross margin expansion.

Adjusted EPS improved 11% Y/Y to 83 cents, beating the consensus of 79 cents.

The company reported an operating cash flow of $257 million and a free cash flow of $230 million (up 54%) in the quarter.

“Our results in the first quarter once again reflect the resiliency and strength of our differentiated portfolio of businesses. All three segments performed ahead of expectations on core growth, margins, earnings growth, and free cash flow, all enabled by the strength and rigorous application of the Fortive Business System (FBS),” said James A. Lico, President and CEO.

Dividend: Fortiv declared a quarterly cash dividend per share of $0.08, payable on June 28, 2024, to stockholders of record on May 31, 2024.

Outlook: For FY24, Fortive ( FTV ) lowered its revenue forecast from $6.4 billion-$6.5 billion to $6.35 billion-$6.43 billion (versus a consensus of $6.48 billion).

Adjusted EPS raised from $3.73-$3.85 to $3.77-$3.86 versus the consensus of $3.80.

For the second quarter of FY24, Fortive ( FTV ) anticipates revenue of approximately $1.6 billion (consensus: $1.62 billion) and adjusted EPS of $0.90-$0.93 (consensus $0.94).

Investors can gain exposure to the stock via Brookstone Intermediate Bond ETF Brookstone Growth Stock ETF  and Pacer US Cash Cows Growth ETF ( BUL ) .

Price Action: FTV shares are trading lower by 7.24% at $74.86 at the last check Wednesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
-- Almadex Minerals Brief: Providing An Overview of Its Diversified Portfolio of Royalties On Precious and Base Metal Projects Throughout North America
-- Almadex Minerals Brief: Providing An Overview of Its Diversified Portfolio of Royalties On Precious and Base Metal Projects Throughout North America
Nov 4, 2025
02:27 PM EST, 11/04/2025 (MT Newswires) -- Price: 0.46, Change: -0.02, Percent Change: -4.17 ...
Market Chatter: Amazon.com Demands Perplexity to Stop Using AI Agent Comet for Online Purchases
Market Chatter: Amazon.com Demands Perplexity to Stop Using AI Agent Comet for Online Purchases
Nov 4, 2025
02:25 PM EST, 11/04/2025 (MT Newswires) -- Amazon.com ( AMZN ) has sent a cease-and-desist letter to Perplexity AI, demanding it to stop allowing its Comet browser agent to make online purchases for users, Bloomberg News reported Tuesday, citing unnamed people familiar with the letter. The e-commerce giant claims that the tool violates its terms of service, and harms the...
China's WeRide prices HK listing, seeks to raise $307.7 million
China's WeRide prices HK listing, seeks to raise $307.7 million
Nov 4, 2025
Nov 4 (Reuters) - Chinese autonomous-driving firm WeRide ( WRD ) on Tuesday set the final offer price for its Hong Kong share sale at HK$27.10 per share, saying it expects to raise HK$2.39 billion ($307.69 million) from the listing. The Guangzhou-based company said it will offer about 88.3 million shares at HK$27.10 each and expects trading to begin on...
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
Nov 4, 2025
The U.S. Food and Drug Administration (FDA) on Monday provided feedback to uniQure N.V. regarding its investigational gene therapy for Huntington's disease. QURE is among today's weakest performers. Stay ahead of the curve here uniQure believes that the FDA currently disagrees that the data from the Phase 1/2 studies of AMT-130, in comparison to an external control, as per the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved